Sudarshan Hebbar - 19 Aug 2026 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: Chief Medical Officer
Issuer ticker: CALC
Reported as of: 19 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Aug 2026, 18:40:57 UTC
Prior SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John Dunn, Attorney-in-Fact

Key filing fact

Sudarshan Hebbar filed Form 4 for CalciMedica, Inc. (CALC) on 21 Aug 2026.

Key facts

This page summarizes Sudarshan Hebbar's Form 4 filing for CalciMedica, Inc. (CALC).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 21 Aug 2026, 18:40.

Change

Previous filing in this sequence was filed on 29 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001968793 Primary reporting owner

Hebbar Sudarshan

Relationship: Chief Medical Officer
Address: C/O CALCIMEDICA, INC., 505 COAST S. BLVD. #307, LA JOLLA
Signature: /s/ John Dunn, Attorney-in-Fact
Signature date: 21 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Warrant

Award

Transaction value
Shares: +124,486
Change %
Price: $0.000000^*
Shares after: 124,486
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 124,486
Exercise price: $0.8033
Footnotes: F1, F2

CALC transaction Derivative

Warrant

Award

Transaction value
Shares: +124,486
Change %
Price: $0.000000^*
Shares after: 124,486
Date: 19 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 124,486
Exercise price: $1.00
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

Footnote F2

The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

Footnote F3

The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.